---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-099444"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2022-09-13T23:59:59+00:00"
generated_at: "2026-06-23T09:58:30.395520+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gail Farfel named CEO of ProMIS Neurosciences effective Sept 19, 2022; Eugene Williams stays Chairman

## Summary
- Gail Farfel appointed CEO effective Sept 19, 2022; Eugene Williams steps down as CEO but remains Chairman.
- Dr. Farfel's base salary $500K (up to $535K after raising $75M), 50% bonus target, 208,334 stock options, $25K sign-on.
- Eugene Williams to receive $225K/yr as consultant for 3 years, plus severance on signing release.
- Dr. Farfel previously Chief Development Officer at Zogenix; led Fintepla Phase 3 and approvals for Dravet/LGS.

## SEC filing metadata
- accession: 0001104659-22-099444
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2022-09-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/0001104659-22-099444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/tm2225652d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-099444
- JSON: https://secwatch.observer/filing/0001104659-22-099444.json
- Plain text: https://secwatch.observer/filing/0001104659-22-099444.txt

## Key facts
- Executive change
  Eugene Williams departed as Chief Executive Officer at ProMIS Neurosciences Inc..
  - Action: stepped down
  - Role: Chief Executive Officer
  source text: Eugene Williams, the Company’s Chief Executive Officer and principal executive officer will step down from his officer position with the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/0001104659-22-099444-index.htm
- Executive change
  Gail Farfel was appointed as Chief Executive Officer at ProMIS Neurosciences Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board of Directors (the " Board ") of the Company approved the appointment of Gail Farfel, Ph.D. as the Company’s Chief Executive Officer, effective September 19, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/0001104659-22-099444-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.